Central DuPage Hospital Enrolls First Illinois Patient in a Clinical Trial for a Novel Device Used in the Treatment of Acute Ischemic Stroke

WINFIELD, Ill., Oct. 26, 2011 /PRNewswire-USNewswire/ -- Central DuPage Hospital (CDH) in Winfield, Ill., has joined efforts with a select number of hospitals nationwide by participating in a new clinical trial evaluating the Trevo® Retrieval System, a novel device for removing clots from the brain in patients experiencing an acute ischemic stroke. Illinois' first patient was enrolled and successfully treated at CDH by interventional neuroradiologist, Harish Shownkeen, M.D., co-medical director of the Stroke & Neurovascular Program.

Following the treatment of the first patient, Dr. Shownkeen said, "I am extremely pleased with the patient's outcome. Participating in trials like TREVO 2 is very important to my team as we continue to expand our stroke toolkit."

The TREVO 2 Study ( T hrombectomy RE vascularization of large V essel O cclusions in acute ischemic stroke) is a randomized, multicenter, prospective trial approved by the Food and Drug Administration (FDA) to evaluate the Trevo Retrieval System. TREVO 2 is designed to assess the ability of the Trevo System to remove the blood clots that cause strokes and to restore blood flow to the brain. Functional outcomes at 90 days will be collected and analyzed.

Back to top

Central DuPage Hospital Enrolls First Illinois Patient in a Clinical Trial for a Novel Device Used in the Treatment of Acute Ischemic Stroke

WINFIELD, Ill., Oct. 26, 2011 /PRNewswire-USNewswire/ -- Central DuPage Hospital (CDH) in Winfield, Ill., has joined efforts with a select number of hospitals nationwide by participating in a new clinical trial evaluating the Trevo® Retrieval System, a novel device for removing clots from the brain in patients experiencing an acute ischemic stroke. Illinois' first patient was enrolled and successfully treated at CDH by interventional neuroradiologist, Harish Shownkeen, M.D., co-medical director of the Stroke & Neurovascular Program.

Following the treatment of the first patient, Dr. Shownkeen said, "I am extremely pleased with the patient's outcome. Participating in trials like TREVO 2 is very important to my team as we continue to expand our stroke toolkit."

The TREVO 2 Study ( T hrombectomy RE vascularization of large V essel O cclusions in acute ischemic stroke) is a randomized, multicenter, prospective trial approved by the Food and Drug Administration (FDA) to evaluate the Trevo Retrieval System. TREVO 2 is designed to assess the ability of the Trevo System to remove the blood clots that cause strokes and to restore blood flow to the brain. Functional outcomes at 90 days will be collected and analyzed.

Back to top